Inno Medicine Secures Nearly $110M+ to Advance Targeted Nanomedicines for Atherosclerosis and Glioma
Beijing-based Inno Medicine has raised nearly RMB 800 million (roughly $110 million-plus) in a Series D financing, giving the Chinese nanomedicine developer substantial new capital as its two flagship programs move deeper into global clinical…
Lumiere Therapeutics Raises Over RMB 100 Million to Advance Epigenetic Editing Therapies
Lumiere Therapeutics has raised more than RMB 100 million (approximately $14 million) in a Pre-A financing round, giving the Chinese gene-editing company fresh capital to push its epigenetic editing programs toward the clinic. The financing was co-led by…
Leaderna Therapeutics Completes Series A+ Financing to Advance Small Nucleic Acid Drug Pipeline
Chengdu-based Leaderna Therapeutics has completed a Series A+ financing round backed exclusively by Grand View Capital, adding fresh capital to accelerate clinical development of its small nucleic acid drug pipeline and further develop its extrahepatic…
Hopstem completes nearly 200 million yuan Series C financing to accelerate its core iPSC programs.
On August 10, 2026, Zhejiang Hopstem Biotechnology Co., Ltd. (or Hopstem) announced the completion of the first tranche of its nearly RMB 200 million Series C financing. This round of financing was jointly participated in by new shareholders Tasly…